Uncertainty surrounding potential US tariffs is threatening to disrupt India's booming pharma deal market, according to Rothschild & Co. While short-term M&A activity may slow due to a lack of confidence and predictability, the industry remains resilient in the long run.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u4w5GE3
via IFTTT
No comments:
Post a Comment